PAHC Stock Gets Increased EPS Forecast from Zacks Research

Phibro Animal Health Corporation (NASDAQ:PAHC) – Zacks Research boosted their Q3 2027 earnings per share (EPS) estimates for Phibro Animal Health in a research report issued to clients and investors on Friday, October 23rd. Zacks Research analyst Team now expects that the company will post earnings per share of $0.83 for the quarter, up from their previous forecast of $0.82. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $3.49 per share. Zacks Research also issued estimates for Phibro Animal Health’s FY2027 earnings at $3.47 EPS, Q1 2028 earnings at $0.84 EPS, FY2028 earnings at $3.66 EPS and FY2029 earnings at $3.88 EPS.

Separately, Weiss Ratings reissued a “hold (c+)” rating on shares of Phibro Animal Health in a research note on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $47.67.

Phibro Animal Health Stock Up 0.6%

Shares of PAHC opened at $39.03 on Monday. The firm has a market cap of $1.58 billion, a P/E ratio of 16.00 and a beta of 0.42. Phibro Animal Health has a 12 month low of $28.25 and a 12 month high of $60.08. The stock’s 50 day moving average is $36.62 and its two-hundred day moving average is $41.14. The company has a current ratio of 2.96, a quick ratio of 1.27 and a debt-to-equity ratio of 1.84.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, August 26th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.14. The company had revenue of $396.75 million during the quarter, compared to analysts’ expectations of $381.18 million. Phibro Animal Health had a net margin of 6.57% and a return on equity of 37.86%. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PAHC. KBC Group NV purchased a new stake in Phibro Animal Health during the 1st quarter worth approximately $29,000. Sterling Capital Management LLC lifted its position in shares of Phibro Animal Health by 864.9% in the third quarter. Sterling Capital Management LLC now owns 714 shares of the company’s stock valued at $26,000 after acquiring an additional 640 shares in the last quarter. Inspire Investing LLC purchased a new position in shares of Phibro Animal Health in the first quarter valued at approximately $158,000. Sanctuary Advisors LLC purchased a new position in shares of Phibro Animal Health in the first quarter valued at approximately $247,000. Finally, Fifth Third Bancorp boosted its stake in shares of Phibro Animal Health by 2,050.0% in the first quarter. Fifth Third Bancorp now owns 4,558 shares of the company’s stock worth $252,000 after acquiring an additional 4,346 shares during the last quarter. 99.34% of the stock is owned by hedge funds and other institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation develops, manufactures and sells products designed to support the health, nutrition and productivity of food-producing animals. Its offerings include animal health products, vaccines, medicated feed additives, nutritional specialties and performance products used in livestock, poultry and aquaculture.

The company’s products are intended to help prevent and manage disease, improve animal well-being and support efficient food production. Phibro serves producers, veterinarians, feed manufacturers and distributors through a portfolio that includes pharmaceuticals, vaccines, mineral and nutritional supplements, and other feed and water solutions.

Phibro Animal Health markets its products internationally across a broad range of geographic regions, including North America, Latin America, Europe, Asia-Pacific and other global markets.